Data From Innovative BiTE® Platform Include First Clinical Data for AMG 701 and Analyses From BLINCYTO® (blinatumomab) Phase 3 Pediatric Study
New KYPROLIS® (carfilzomib) Progression-Free Survival Data From the Phase 3 CANDOR Study
PR Newswire
THOUSAND OAKS, Calif., Nov. 30, 2020